ERBB2 and breast cancer: Neratinib achieved an overall response rate (ORR) of 12.5%–32% in ERBB2 mutant BC, whereas in similar patients with non-small cell lung cancer (NSCLC) had no or very limited benefit (0%–4% ORR).